For fourth-quarter 2008, Pfizer posted

online currency trading

star online foreign exchange

online currency trading

Our combined company will be one of the most diversified in the industry and will benefit from complementary patient-centric units that match speed with the benefits of a global company €™s scale and resources, € continued Kindler. These charges include approximately $1.1 billion of intangible asset impairments, $661 million of inventory write-offs, $454 million of fixed asset impairments, and $578 million of other exit costs. In fourth-quarter 2008, adjusted

forex trading

2008 Actual 2009 Guidance Adjusted Revenues(1) $48.3 billion $44.0 to

foreign exchange

currency market

foreign exchange

money market

forex trade

forex micro trading

forex trading

fx trading

money market

mini forex trading

(5) Represents worldwide revenues for pharmaceutical products launched since 2006. As described under Adjusted Income in the Management €™s Discussion and Analysis of Financial

foreign currency trading

forex trading reviews

forex

forex micro trading

forex

currency trade

currency trade

foreign currency trading

currency market

forex trade

fx trading

currency trading

Full-year 2008

currency trading

crown forex reviews

cms forex reviews

International reported revenues were $7.1 billion, a decrease of 1% compared with the year-ago quarter, and reflect operational growth of 5%, which was more than offset by the unfavorable impact of foreign exchange of 6%. Full-year revenues were favorably impacted by foreign exchange of approximately $1.6 billion, or 3%, and the solid performance of many key products. Adjusted Revenues , Adjusted Income and Adjusted Diluted EPS Results For fourth-quarter 2008, Pfizer posted adjusted revenues(1) of $12.3 billion, a decrease of 4% compared with $12.8 billion in the year-ago quarter.

Cost of sales (a) 2,625 - - - (359 ) 2,266 Selling, informational and administrative expenses (a) 4,653 3 - - (124 ) 4,532 Research and development expenses (a) 2,260 (7 ) - - (93 ) 2,160 Amortization of intangible assets 756 (721 ) - - - 35 Acquisition-related in-process R&D charges - - - - - - Restructuring charges and acquisition-related costs 216 - (3 ) - (213 ) - Other (income)/deductions--net (610 ) (2 ) - - 219 (393 ) Income from continuing operations before provision/(benefit) for taxes on income and minority interests 2,970 727 3 - 495 4,195 Provision/(benefit) for taxes on income 223 219 (4 ) - 319 757 Minority interests 36 - - - - 36 Income from continuing operations 2,711 508 7 - 176 3,402 Discontinued operations. Fourth-quarter 2008 adjusted income(1) was $4.4 billion, an increase of 29% compared with $3.4 billion in the year-ago quarter, and adjusted diluted EPS(1) was $0.65, an increase of 30% compared with $0.50 in the year-ago quarter. For fourth-quarter 2008, the Company recorded reported revenues of $12.3 billion, a decrease of 4% compared with the year-ago quarter. Further, its robust life cycle plan currently includes Phase 3 clinical trials in cancers with unmet medical need, such as breast, lung, colorectal, liver and prostate cancers. Amortization expense related to acquired intangible assets that are associated with a single function are included in Cost of sales, Selling, informational and administrative expenses or Research and development expenses, as appropriate.

(6) Total worldwide pharmaceutical revenues excluding the revenues of major products that have lost exclusivity in the U.S. Subsidiaries operating outside the United States are included for the three-month and twelve-month periods ended of each year. As required through , the estimated value of Acquisition-related in-process research and development charges (IPR&D) is expensed at acquisition date. This also assumes a

forex charting software reviews

For full-year 2008, adjusted R&D expenses(1) were $7.5 billion, a decrease of 1% compared with 2007. For the full-year 2008, adjusted SI&A expenses(1) were $14.0 billion, a decrease of 8% compared with 2007. Adjusted selling, informational and administrative (SI&A) expenses(1) were $3.5 billion in fourth-quarter 2008, a decrease of 23% compared with the prior-year quarter. (3) Constant currency basis means that the applicable financial forex peace army fap turbo measure is based upon the actual foreign exchange rates in effect during 2006. Reductions will span sales, manufacturing, research and development, and administrative organizations. € €œAs part of this advancement, today we announced that we have entered into an agreement to acquire Wyeth to create the

forex trading online training

Certain amounts may reflect rounding adjustments. It also reflects an increase in the effective tax rate resulting from financial strategies in connection with the proposed acquisition of Wyeth. Pharmaceutical revenues for fourth-quarter 2008 were $11.2 billion, a decrease of 4% compared with the prior-year quarter, including the unfavorable impact of foreign exchange of approximately $340 million or 3%. Full-year 2008 adjusted income(1) was $16.4 billion, an increase of 8% compared with $15.1 billion in the year-ago period, and adjusted diluted EPS(1) was $2.42, an increase of 11% compared with $2.18. In addition, foreign exchange unfavorably impacted reported revenues

forex minimum deposit

(9) Current exchange rates approximate rates at the time of the fourth-quarter 2008 earnings (January 2009). Amortization expense related to acquired intangible assets that are associated with a single function are included in Cost of sales, Selling, informational and administrative expenses or Research and development expenses, as appropriate. Full-year 2008 Animal Health revenues were $2.8 billion, an increase of 7% compared with $2.6 billion in 2007, driven by strong global livestock and companion animal product performance. In addition, full-year 2008 pharmaceutical revenues were negatively impacted by a $217 million adjustment to the prior years €™ product returns liabilities recorded in third-quarter 2008.

Adjusted research and development (R&D) expenses(1) were $2.2 billion in fourth-quarter 2008, an increase of 2% compared with the prior-year period. Foreign exchange positively impacted fourth-quarter 2008 by $103 million and negatively impacted full-year 2008 by $379 million compared with the respective year-ago periods. Chantix has now been launched in all major markets, with nine launches planned in 2009 in emerging markets. Foreign exchange increased full-year 2008 adjusted total costs(2) by $312 million or 1% compared with 2007. Provision for taxes on income includes a tax benefit of $278 million in the fourth quarter of 2007 and a tax benefit of $958 million for full-year 2007 relating to charges associated with Exubera.

online forex trading course

Both adjusted income(1) and adjusted diluted EPS(1) were positively impacted by savings associated with our cost-reduction initiatives and higher fourth-quarter 2007 spending levels in comparison with fourth-quarter 2008, partially offset by an increase in the effective tax rate. Income from continuing operations $ 1.19 $ 0.36 $ - $ - $ 0.87 $ 2.42 Discontinued operations--net of tax 0.01 - - (0.01 ) - - Net income $ 1.20 $ 0.36 $ - $ (0.01 ) $ 0.87 $ 2.42 (a) Exclusive of amortization of intangible assets, except as discussed in note 1. Approximately $1 billion of these savings will be reinvested in the business, resulting in an expected $2 billion net decrease. In addition, results were unfavorably impacted by an increased effective tax rate, as well as an increase in pre-tax charges of $1.2 billion ($700 million after-tax) associated with cost-reduction initiatives, which were partially offset by savings from those initiatives. PFIZER INC AND SUBSIDIARY COMPANIES RECONCILIATION OF REPORTED NET INCOME AND ITS COMPONENTS AND REPORTED DILUTED EPS TO ADJUSTED INCOME AND ITS COMPONENTS AND ADJUSTED DILUTED EPS (UNAUDITED) (millions of dollars, except per com share data) Quarter Ended Purchase Acquisition- Certain Accounting Related Discontinued Significant Reported Adjustments Costs Operations Items(2) Adjusted Revenues $ 12,870 $ - $ - $ - $ (75 ) $ 12,795 Costs and expenses. For the full-year 2008, adjusted cost of sales(1) as a percentage of revenues was 14.6% compared with 16.0% in 2007, an improvement from our previous guidance of 15.0% to 15.5%. The operational improvement was driven partially by the reduction in workforce to approximately 81,900 at year-end 2008, a decline of 4,700 compared with the year-end 2007, as well as manufacturing and research and development site exits. Income/(loss) from discontinued operations--net of tax (3 ) - - 3 - - Gains/(losses) on sales of discontinued operations--net of tax 16 - - (16 ) - - Discontinued operations--net of tax 13 - - (13 ) - -

forex trading signals review

Included in Cost of sales ($700 million), Selling, informational and administrative expenses ($334 million), Research and development expenses ($416 million), and Other (income)/deductions - net ($61 million income) for the full year ended. Pfizer will implement a new cost-reduction initiative, which is expected to achieve incremental cost savings of approximately $3 billion, at 2008 average foreign exchange rates, compared with 2008 adjusted total costs(2) of $28.6 billion. Income from continuing operations $ 0.03 $ 0.40 (93 ) $ 1.19 $ 1.19 - Discontinued operations--net of tax 0.01 - 0.01 (0.01 ) Net income $ 0.04 $ 0.40 (90 ) $ 1.20 $ 1.18 2 Earnings per com share - diluted. In the U.S., Sutent revenues were $66 million, an increase of 5% year over year, while international revenues were $154 million, an increase of 30%. 2) Certain significant items includes the following.

Included in Revenues ($172 million), Cost of sales ($162 million) and Selling, informational and administrative expenses ($3 million) for the full year ended. Results continued to be negatively impacted by the changes to the Chantix U.S. The charges are primarily included in Cost of sales ($2.6 billion), Selling, informational and administrative expenses ($85 million) and Research and development expenses ($100 million). In the U.S., Chantix revenues were $91 million, a decline of 55% compared with the prior-year quarter, while international revenues were $89 million, an increase of 13%. PFIZER INC AND SUBSIDIARY COMPANIES RECONCILIATION OF REPORTED NET INCOME AND ITS COMPONENTS AND REPORTED DILUTED EPS TO ADJUSTED INCOME AND ITS COMPONENTS AND ADJUSTED DILUTED EPS (UNAUDITED) (millions of dollars, except per com share data) Quarter Ended Purchase Acquisition- Certain Accounting Related Discontinued Significant Reported Adjustments Costs Operations Items(2) Adjusted Revenues $ 12,346 $ - $ - $ - $ (35 ) $ 12,311 Costs and expenses. These factors contributed to a reduction in our Adjusted Diluted EPS(1) of approximately $0.50. (10) Does not assume the completion of any business

forex

Certain amounts and percentages may reflect rounding adjustments. And Auxilium Pharmaceuticals, Inc. 30% Reported Diluted EPS(10) $1.20 $1.34 to $1.49 Adjusted Diluted EPS(1) $2.42 $1.85 to $1.95 For additional details, please see the attached financial schedules, product revenue tables, supplemental information and disclosure notice. / (Decr.) Full-Year % Incr. The combination of Pfizer and Wyeth will meaningfully deliver Pfizer €™s strategic priorities in a single transaction. Exclusivity for Zyrtec in and for Camptosar in as well as the loss of exclusivity for Norvasc in Korea and Japan in and July 2008, respectively. Lipitor revenues in fourth-quarter 2008 were $3.1 billion, a decrease of 8% compared with the prior-year quarter.

Included in Revenues ($219 million), Cost of sales ($194 million), Selling, informational and administrative expenses ($15 million), and Other (income)/ deductions - net ($16 million income) for the full year ended. Reconciliations of fourth-quarter 2008 and 2007 and full-year 2008 and 2007 adjusted income and its components and adjusted diluted EPS to reported net income and its components and reported diluted EPS, as well as reconciliations of full-year 2009 adjusted income and adjusted diluted EPS guidance to full-year 2009 reported net income and reported diluted EPS guidance, are provided in the materials accompanying this report. Dollar, € stated D €™Amelio. PFIZER INC SEGMENT/PRODUCT REVENUES FOURTH QUARTER 2008 (UNAUDITED) (millions of dollars) QUARTER-TO-DATE WORLDWIDE U.S. ($ in millions,

live forex quotes

easy forex reviews

In the U.S., Lipitor revenues were $1.6 billion, a decrease of 13% compared with the prior-year quarter. Included in Cost of sales ($745 million), Selling, informational and administrative expenses ($413 million), Research and development expenses ($433 million), and Other (income)/deductions - net ($14 million) for the full year ended. Reported revenues accounted for 43% of the total compared with 44% in the year-ago quarter, while international reported revenues accounted for 57% of the total compared with 56% in the year-ago quarter.

The adjusted income and its components and adjusted diluted EPS measures are not, and should not be vie as, substitutes for U.S. The financial results for the full year ended , include pre-tax charges of $2.8 billion, virtually all of which were recorded in the third quarter of 2007, associated with the impairment of Exubera assets and the decision to exit and stop additional investment in the product. This improvement reflects the benefits from our cost-reduction initiatives and foreign exchange. The program will be substantially complete by the end of 2010, with the full savings to be realized by the end of 2011. / (Decr.) 2008 2007 2008 2007 Revenues $ 12,346 $ 12,870 (4 ) $ 48,296 $ 48,418 - Costs and expenses. Reported and adjusted diluted EPS(1) were also positively impacted by the full benefit of Pfizer €™s purchase of $10.0 billion of the Company €™s com stock in 2007. Zyrtec, Camptosar and Norvasc fourth-quarter 2008 revenues decreased by $515 million ($263 million, $144 million and $108 million, respectively), compared with the year-ago quarter.

€ €œFurther, as part of the proposed acquisition of Wyeth, we expect to achieve synergies of approximately $4 billion by the end of 2012, which will be in addition to the savings from our previous cost-reduction initiatives, € continued D €™Amelio. In fourth-quarter 2008, foreign exchange unfavorably impacted revenues by approximately $35 million or 4%, while in full-year 2008, foreign exchange positively impacted revenues by approximately $80 million or 3%, compared with the prior-year respective periods. Excluding the impact of foreign exchange, full-year 2008 adjusted total costs(2) decreased by approximately $2.2 billion, or 7%, compared with 2007. For full-year 2008, Pfizer recorded reported revenues of $48.3 billion, essentially flat compared with 2007 full-year revenues of $48.4 billion, despite the loss of exclusivity of Norvasc, Zyrtec and Camptosar, which collectively decreased revenues by $2.6 billion. PFIZER INC AND SUBSIDIARY COMPANIES NOTES TO RECONCILIATION OF REPORTED NET INCOME AND ITS COMPONENTS AND REPORTED DILUTED EPS TO ADJUSTED INCOME AND ITS COMPONENTS AND ADJUSTED DILUTED EPS (UNAUDITED) 1) Amortization expense related to acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute our products are included in Amortization of intangible assets as they benefit multiple business

retail forex trading

forex robot review

online currency trading india

Notwithstanding an extremely competitive and increasingly challenging environment in 2008, we made significant progress by. Cost of sales (a) 11,239 (49 ) - - (3,497 ) 7,693

currency trading online

forex metatrader review

forex market india

historical money market rates

Fourth-quarter 2008 results were impacted by a $2.3 billion pre-tax and after-tax charge resulting from an agreement in principle with the Office of Jorgan Sullivan, the United States Attorney for the District of Massachusetts, to resolve previously disclosed investigations regarding allegations of past off-label promotional practices concerning Bextra, as well as other open investigations. The increase in fourth-quarter 2008 is primarily the result of up-front payments totaling $300 million related to the licensing agreements with Medivation, Inc. (c) Included in Other (income)/deductions - net and for the full year ended , includes charges of approximately $900 million, recorded in the third quarter of 2008, associated with the resolution of certain litigation involving our non-steroidal anti-inflammatory pain medicines and charges of approximately $2.3 billion, recorded in the fourth quarter of 2008, resulting from an agreement in principle to resolve previously disclosed investigations regarding allegations of past off-label promotional practices concerning Bextra, as well as other open investigations. Lyrica revenues in fourth-quarter 2008 were $702 million, a year-over-year increase of 25%, driven by strong physician prescribing patterns and patient satisfaction, as well

trade forex

The anticipated net savings from this new initiative in addition to the savings we achieved at year-end 2008 under our previous cost-reduction initiative total approximately $4.8 billion. This was primarily attributable to savings associated with our cost-reduction initiatives, the 2007 after-tax charges of $1.8 billion related to the decision to exit Exubera and the favorable impact of foreign exchange, offset by the aforementioned charge related to Bextra and other open investigations in fourth-quarter 2008, as well as the after-tax charge of $640 million resulting from the agreements in principle to resolve certain litigation involving the Company €™s non-steroidal anti-inflammatory (NSAID) pain medicines in third-quarter 2008 and an increased effective tax rate. Excluding the impact of foreign exchange, adjusted cost of sales(1) as a percentage of revenues was 15.6% in fourth-quarter 2008 and 15.2% for the full-year 2008.

Cost of sales (a) 1,715 2,625 (35 ) 8,112 11,239 (28 ) Selling, informational and administrative expenses (a) 3,659 4,653 (21 ) 14,537 15,626 (7 ) Research and development expenses (a) 2,303 2,260 2 7,945 8,089 (2 ) Amortization of intangible assets 605 756 (20 ) 2,668 3,128 (15 ) Acquisition-related in-process research and development charges 66 - 633 283

forex mini

Frank D €™Amelio, Chief Financial Officer, stated, €œIn 2008, we exceeded our cost-reduction target by decreasing our adjusted total costs(2) by $2.8 billion in comparison to 2006 on a constant currency basis(3). Included in Revenues ($75 million), Cost of sales ($73 million), Selling, informational and administrative expenses ($3 million), and Other (income)/deductions - net ($3 million income) for the three months ended. Income/(loss) from discontinued operations--net of tax (2 ) - - 2 - - Gains/(losses) on sales of discontinued operations--net of tax 80 - - (80 ) - - Discontinued operations--net of tax 78 - - (78 ) - - Net income $ 8,104 $ 2,439 $ 39 $ (78 ) $ 5,862 $ 16,366 Earnings per com share - diluted.

We

online forex brokers

Adjusted revenues(1) in both periods were positively impacted by the solid performance of key products, and negatively impacted by the loss of exclusivity of Norvasc, Zyrtec and Camptosar. NEW YORK-- --Pfizer Inc (NYSE. In addition, foreign exchange unfavorably impacted fourth-quarter 2008 revenues compared with the year-ago period by $389 million, but favorably impacted full-year 2008 revenues by $1.6 billion compared with the prior year.

(7) Represents worldwide revenues for pharmaceutical products that lost exclusivity in 2007 and 2008. Calculation not meaningful. Sutent is available in all major markets and is supported by efficacy, survival and cost-effectiveness data. The 2009 financial guidance, in comparison with 2008 financial results, reflects the projected impact of the strengthening of the U.S. In the first quarter of 2007, we expensed $283 million of IPR&D, primarily related to our acquisitions of BioRexis Pharmaceutical Corp. During 2008, we expensed $633 million of IPR&D, primarily related to our acquisitions of Serenex, Inc., Encysive Pharmaceuticals, Inc., CovX, Coley Pharmaceutical Group, Inc. Provision for taxes on income for fourth-quarter

foreign currency trading

This decrease was primarily attributable to the negative impact of the loss of U.S. Dollar, increased pension expenses and lower interest income. In conjunction with this program, Pfizer expects to incur costs of approximately $6 billion on a pre-tax basis, of which $1.5 billion has been incurred. For full-year 2009, Pfizer €™s financial guidance, at current exchange rates(9) is summarized below.

Cost of sales (a) 1,715 - - - (271 ) 1,444 Selling, informational and administrative expenses (a) 3,659 3 - - (152 ) 3,510 Research and development expenses (a) 2,303 (6 ) - - (85 ) 2,212 Amortization of intangible assets 605 (560 ) - - - 45 Acquisition-related in-process R&D charges 66 (66 ) - - - - Restructuring charges and acquisition-related costs 1,562 - (13 ) - (1,549 ) - Other (income)/deductions--net 1,811 (2 ) - - (2,452 ) (643 ) Income from continuing operations before provision for taxes on income and minority interests 625 631 13 - 4,474 5,743 Provision for taxes on income 394 190 4 - 761 1,349 Minority interests 5 - - - - 5 Income from continuing operations 226 441 9 - 3,713 4,389 Discontinued operations. Loss from discontinued operations--net of tax 2 (3 )

forex loan online trading

Reported revenues accounted for 42% of the total compared with 48% in the year-ago period, while international reported revenues accounted for 58% of the total compared with 52% in the year-ago period. (b) Included in Cost of sales ($225 million), Selling, informational and administrative expenses ($143 million), Research and development expenses ($85 million), and Other (income)/deductions - net ($12 million) for the three months ended. In the U.S., Lyrica revenues were $384 million, a year-over-year increase of 20%, while international revenues were $318 million, an increase of 31%, reflecting operational growth of 42% and the unfavorable impact of foreign exchange of 11%.

See end of tables for notes. As part of this cost-reduction initiative, Pfizer intends to reduce its workforce by approximately 10%. Fourth Quarter Twelve Months (millions of dollars) 2008 2007 2008 2007 Restructuring charges - Cost-reduction initiatives(a) $ 1,549 $ 256 $ 2,626 $ 2,523 Implementation costs - Cost-reduction initiatives(b) 465 525 1,605 1,389 Legal matters(c) 2,313 (5 ) 3,249 56 Returns liability adjustment(d) - - 217 - Asset impairment charges and other associated costs(e) 98 (6 ) 213 2,798 Consumer Healthcare business transition activity(f) (4 ) (2 ) (7 ) (26 ) Other 53 (273 ) 187 (230 ) Total certain significant items, pre-tax 4,474 495 8,090 6,510 Income taxes(g) (761 ) (319 ) (2,228 ) (2,131 ) Total certain significant items--net of tax $ 3,713 $ 176 $ 5,862 $ 4,379 (a) Included in Restructuring charges and acquisition-related costs. €œIn 2009, Pfizer expects to generate revenues of $44.0 to $46.0 billion, and adjusted diluted EPS(1) of $1.85 to $1.95, which includes most of the anticipated $1 billion investment intended to create new sources of revenue. (2) Represents primarily the total of Adjusted Cost of Sales(1), Adjusted SI&A expenses(1) and Adjusted R&D expenses(1). Reported revenues were $20.4 billion, a decrease of 12% year over year, while international reported revenues were $27.9 billion, an increase of 10%, reflecting the favorable impact of foreign exchange of 6% and operational growth of 4%. PFIZER INC AND SUBSIDIARY COMPANIES CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) (millions of dollars, except per com share data) Fourth-Quarter % Incr.

Celebrex revenues in fourth-quarter 2008 were $664 million, an increase of 4% compared with the year-ago quarter, supported by continued educational and promotional efforts highlighting the benefit-risk proposition of Celebrex. (4) Represents worldwide revenues for all pharmaceutical products, excluding revenues included in notes (5) and (7). Chantix (known as Champix outside the U.S.) revenues in fourth-quarter 2008 were $180 million, a decrease of 36% year over year. Income from continuing operations $ 0.40 $ 0.07 $ - $ - $ 0.03 $ 0.50 Discontinued operations--net of tax - - - - - - Net income $ 0.40 $ 0.07 $ - $ - $ 0.03 $ 0.50 Twelve Months Ended Purchase Acquisition- Certain Accounting Related Discontinued Significant Reported Adjustments Costs Operations Items(2) Adjusted Revenues $ 48,418 $ - $ - $ - $ (209 ) $ 48,209 Costs and expenses. €œWe are pleased with our performance in 2008, € said Chairman and Chief Executive Skelly Kindler. Revenues from international markets were $1.5 billion, a decrease of 2%, reflecting the unfavorable impact of foreign exchange of approximately $124 million, or 8%, which more than offset operational growth of 6%.

Adjusted Revenues, Adjusted Cost of Sales, Adjusted SI&A expenses, Adjusted R&D expenses and Adjusted Other (Income)/Deductions-net are income statement line items prepared on the same basis, and therefore, components of the overall adjusted income measure. With this initiative and our recently completed initiative, the Company expects to reduce adjusted total costs(2) by about $4.8 billion while absorbing inflation and compensation increases. Provision for taxes on income for fourth-quarter and full-year 2008 also reflects the impact of the fourth-quarter 2008 legal settlement provisions, which are either not deductible or deductible at lower tax rates. For full-year 2008, Pfizer posted adjusted revenues(1) of $48.3 billion, essentially flat compared with $48.2 billion in full-year 2007. Chantix/Champix, Eraxis, Selzentry/Celsentri, Sutent, Thelin and Toviaz. INTERNATIONAL Change Change Change TOTAL REVENUES PHARMACEUTICAL - CARDIOVASCULAR AND METABOLIC DISEASES LIPITOR 3,146 3,428 (8) 1,615 1,864 (13) 1,531 1,564 (2) NORVASC 542 650 (16) 17 26 (34) 525 624 (16) CHANTIX / CHAMPIX 180 280 (36) 91 202 (55) 89 78 13 CADUET 148 154 (5) 117 125 (7) 31 29 5 CARDURA 121 128 (6) 2 3 (34) 119 125 (6) - CENTRAL NERVOUS SYSTEM DISORDERS LYRICA 702 564 25 384 320 20 318 244 31 GEODON / ZELDOX 276 232 19 228 192 19 48 40 19 ZOLOFT 131 134 (2) 24 25 (4) 107 109 (2) ARICEPT 126 116 9 - - 63 126 116 9 NEURONTIN 92 110 (16) 16 19 (16) 76 91 (16) XANAX / XANAX XR 83 86 (4) 11 16 (29) 72 70 1 RELPAX 81 85 (4) 50 53 (7) 31 32 - - ARTHRITIS AND PAIN CELEBREX 664 637 4 489 469 4 175 168 4 - INFECTIOUS AND RESPIRATORY DISEASES ZYVOX 283 252 13 175 155 13 108 97 13 VFEND 196 177 10 64 57 13 132 120 9 ZITHROMAX / ZMAX 109 110 (1) 2 - 260 107 110 (1) DIFLUCAN 93 104 (11) 2 4 (36) 91 100 (10) - UROLOGY VIAGRA 502 498 1 239 220 9 263 278 (5) DETROL/DETROL LA 313 324 (3) 218 219 - 95 105 (9) - ONCOLOGY SUTENT 220 182 21 66 63 5 154 119 30 CAMPTOSAR 112 256 (56) (4) 142 116 114 2 AROMASIN 123 114 9 39 35 11 84 79 8 - OPHTHALMOLOGY XALATAN / XALACOM 454 453 -. In 2007 and 2008 as described in note (7).

These decreases were primarily due to the favorable impact of our cost-reduction initiatives. At the end of fourth-quarter 2008, Pfizer exceeded its goal to reduce absolute adjusted total costs(2) by at least $2.0 billion by the end of 2008 compared with 2006 on a constant currency basis(3), realizing a total reduction of $2.8 billion. Income from continuing operations $ 0.03 $ 0.40 (93 ) $ 1.19 $ 1.18 1 Discontinued operations--net of tax 0.01 - 0.01 (0.01 ) Net income $ 0.04 $ 0.40 (90 ) $ 1.20 $ 1.17 3 Weighted-average shares used to calculate earnings per com share.

For full-year 2008, the Company posted reported net income of $8.1 billion, essentially flat compared with the prior year, and reported diluted EPS of $1.20, an increase of 3% compared with $1.17.